BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34830757)

  • 1. Oncogenic KRAS: Signaling and Drug Resistance.
    Kim HJ; Lee HN; Jeong MS; Jang SB
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
    Roskoski R
    Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
    Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
    J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.
    Yin G; Kistler S; George SD; Kuhlmann N; Garvey L; Huynh M; Bagni RK; Lammers M; Der CJ; Campbell SL
    J Biol Chem; 2017 Mar; 292(11):4446-4456. PubMed ID: 28154176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules.
    Goody RS; Müller MP; Rauh D
    Cell Chem Biol; 2019 Oct; 26(10):1338-1348. PubMed ID: 31378709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the "undruggable" RAS - new strategies - new hope?
    Mörchen B; Shkura O; Stoll R; Helfrich I
    Cancer Drug Resist; 2019; 2(3):813-826. PubMed ID: 35582595
    [No Abstract]   [Full Text] [Related]  

  • 8. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
    Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
    Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational resolution of nucleotide cycling and effector interactions for multiple small GTPases determined in parallel.
    Killoran RC; Smith MJ
    J Biol Chem; 2019 Jun; 294(25):9937-9948. PubMed ID: 31088913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMR
    Sharma AK; Dyba M; Tonelli M; Smith B; Gillette WK; Esposito D; Nissley DV; McCormick F; Maciag AE
    Biomol NMR Assign; 2022 Apr; 16(1):1-8. PubMed ID: 34686998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guanine nucleotide exchange factors: activators of Ras superfamily proteins.
    Overbeck AF; Brtva TR; Cox AD; Graham SM; Huff SY; Khosravi-Far R; Quilliam LA; Solski PA; Der CJ
    Mol Reprod Dev; 1995 Dec; 42(4):468-76. PubMed ID: 8607978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the RAS-dependent chemoresistance: The Warburg connection.
    Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
    Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of the guanine nucleotide exchange reaction of Ras GTPase--evidence for a GTP/GDP displacement model.
    Zhang B; Zhang Y; Shacter E; Zheng Y
    Biochemistry; 2005 Feb; 44(7):2566-76. PubMed ID: 15709769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
    Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
    Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMR
    Sharma AK; Lee SJ; Rigby AC; Townson SA
    Biomol NMR Assign; 2018 Oct; 12(2):269-272. PubMed ID: 29721757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential dynamics of RAS isoforms in GDP- and GTP-bound states.
    Kapoor A; Travesset A
    Proteins; 2015 Jun; 83(6):1091-106. PubMed ID: 25846136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMR
    Sharma AK; Lee SJ; Zhou M; Rigby AC; Townson SA
    Biomol NMR Assign; 2019 Apr; 13(1):227-231. PubMed ID: 30798456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The GAP1 family of GTPase-activating proteins: spatial and temporal regulators of small GTPase signalling.
    Yarwood S; Bouyoucef-Cherchalli D; Cullen PJ; Kupzig S
    Biochem Soc Trans; 2006 Nov; 34(Pt 5):846-50. PubMed ID: 17052212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct Targeting
    Reita D; Pabst L; Pencreach E; Guérin E; Dano L; Rimelen V; Voegeli AC; Vallat L; Mascaux C; Beau-Faller M
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.